Overview

  • Product name
    Anti-SLC25A13 antibody [EPR9968(B)]
    See all SLC25A13 primary antibodies
  • Description
    Rabbit monoclonal [EPR9968(B)] to SLC25A13
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IHC-Pmore details
    Unsuitable for: Flow Cyt,ICC/IF or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to residues in Human SLC25A13 (Q9UJS0).

  • Positive control
    • Fetal liver, HepG2, and SH-SY5Y cell lysates, Human liver tissue
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.

Applications

Our Abpromise guarantee covers the use of ab156010 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 70 kDa (predicted molecular weight: 74 kDa).
IHC-P 1/50 - 1/100.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF or IP.
  • Target

    • Function
      Catalyzes the calcium-dependent exchange of cytoplasmic glutamate with mitochondrial aspartate across the mitochondrial inner membrane. May have a function in the urea cycle.
    • Tissue specificity
      High levels in liver and low levels in kidney, pancreas, placenta, heart and brain.
    • Involvement in disease
      Defects in SLC25A13 are the cause of citrullinemia type 2 (CTLN2) [MIM:603471]. Citrullinemia belongs to the urea cycle disorders. It is an autosomal recessive disease characterized primarily by elevated serum and urine citrulline levels. Ammonia intoxication is another manifestation. CTLN2 is characterized by neuropsychiatric symptoms including abnormal behaviors, loss of memory, seizures and coma. Death can result from brain edema. Onset is sudden and usually between the ages of 20 and 50 years.
      Defects in SLC25A13 are the cause of neonatal intrahepatic cholestasis due to citrin deficiency (NICCD) [MIM:605814]. NICCD is a form of citrullinemia type 2 with neonatal onset. NICCD is characterized by suppression of the bile flow, hepatic fibrosis, low birth weight, growth retardation, hypoproteinemia, variable liver dysfunction. NICCD is generally not severe and symptoms disappear by one year of age with an appropriate diet. Years or even decades later, however, some individuals develop the characteristic features of citrullinemia type 2 with neuropsychiatric symptoms.
    • Sequence similarities
      Belongs to the mitochondrial carrier family.
      Contains 4 EF-hand domains.
      Contains 3 Solcar repeats.
    • Cellular localization
      Mitochondrion inner membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • AI785475 antibody
      • ARALAR2 antibody
      • Calcium binding mitochondrial carrier protein Aralar2 antibody
      • Calcium-binding mitochondrial carrier protein Aralar2 antibody
      • Citrin antibody
      • CMC2_HUMAN antibody
      • CTLN2 antibody
      • Ctrn antibody
      • Mitochondrial aspartate glutamate carrier 2 antibody
      • RGD1565889 antibody
      • Slc25a13 antibody
      • Solute carrier family 25 (citrin) member 13 antibody
      • Solute carrier family 25 member 13 (citrin) antibody
      • Solute carrier family 25 member 13 antibody
      see all

    Images

    • Lane 1: Wild-type HAP1 cell lysate (40 µg)
      Lane 2: SLC25A13 knockout HAP1 cell lysate (40 µg)
      Lane 3: (40 µg)
      Lane 4: (40 µg)
      Lanes 1 - 4: Merged signal (red and green). Green - ab156010 observed at 70 kDa. Red - loading control, ab8245, observed at 37 kDa.

      ab156010 was shown to recognize SLC25A13 when SLC25A13 knockout samples were used, along with additional cross-reactive bands. Wild-type and SLC25A13  knockout samples were subjected to SDS-PAGE. Ab156010 and ab8245 (loading control to GAPDH) were diluted at 1/500 and 1:10,000 dilution respectively and incubated overnight at 4C. Blots were developed with IRDye® 800CW Goat anti-Rabbit IgG (H + L) and IRDye® 680 Goat anti-Mouse IgG (H + L) secondary antibodies at 1:10,000 dilution for 1 hour at room temperature before imaging.

    • All lanes : Anti-SLC25A13 antibody [EPR9968(B)] (ab156010) at 1/1000 dilution

      Lane 1 : fetal liver cell lysate
      Lane 2 : HepG2 cell lysate
      Lane 3 : SH-SY5Y cell lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size: 74 kDa
      Observed band size: 70 kDa
      why is the actual band size different from the predicted?

    • Immunohistochemical analysis of paraffin embedded Human liver tissue labeling SLC25A13 with ab156010 antibody at 1/50.

    References

    ab156010 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab156010.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up